fosrugocrixan

Fosrugocrixan is an oral small‑molecule prodrug CX3C chemokine receptor 1 (CX3CR1, fractalkine receptor) antagonist developed by Novakand Pharma (formerly Kancera) as a second‑generation fractalkine‑axis blocker for inflammatory cardiovascular diseases and cancer.[1][4][5][8][10] After administration, fosrugocrixan is rapidly converted in vivo to the active moiety rugocrixan (KAND567), providing similar CX3CR1‑blocking pharmacology with improved product properties and oral formulation potential.[1][4][8][10] By selectively blocking CX3CR1, the drug is designed to modulate recruitment and survival of disease‑promoting immune cells in the CX3CL1–CX3CR1 axis across inflammatory conditions, cancers, and autoimmune diseases, with an initial clinical focus on ovarian cancer and exploratory work in other B‑cell malignancies and systemic inflammation.[4][5][7][13][16]